JP2006502160A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502160A5 JP2006502160A5 JP2004534386A JP2004534386A JP2006502160A5 JP 2006502160 A5 JP2006502160 A5 JP 2006502160A5 JP 2004534386 A JP2004534386 A JP 2004534386A JP 2004534386 A JP2004534386 A JP 2004534386A JP 2006502160 A5 JP2006502160 A5 JP 2006502160A5
- Authority
- JP
- Japan
- Prior art keywords
- aerosol
- amino
- ppm
- drug
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 148
- 229940079593 drug Drugs 0.000 claims 140
- 239000000443 aerosol Substances 0.000 claims 130
- 239000000203 mixture Substances 0.000 claims 123
- -1 cromoline Chemical compound 0.000 claims 68
- 238000000034 method Methods 0.000 claims 66
- 239000008194 pharmaceutical composition Substances 0.000 claims 44
- 239000003246 corticosteroid Substances 0.000 claims 41
- 239000003380 propellant Substances 0.000 claims 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 36
- 239000000048 adrenergic agonist Substances 0.000 claims 35
- 239000003381 stabilizer Substances 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 31
- 150000002617 leukotrienes Chemical class 0.000 claims 30
- 239000000812 cholinergic antagonist Substances 0.000 claims 29
- 239000012453 solvate Substances 0.000 claims 27
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 26
- 150000002148 esters Chemical class 0.000 claims 23
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 22
- 229960004436 budesonide Drugs 0.000 claims 22
- 229960002848 formoterol Drugs 0.000 claims 22
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 22
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 21
- 239000006184 cosolvent Substances 0.000 claims 21
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 21
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 21
- 229960002714 fluticasone Drugs 0.000 claims 18
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 18
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 17
- 229960002052 salbutamol Drugs 0.000 claims 17
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 13
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 13
- 229930182837 (R)-adrenaline Natural products 0.000 claims 13
- 229930003347 Atropine Natural products 0.000 claims 13
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 13
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 13
- 239000000739 antihistaminic agent Substances 0.000 claims 13
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 13
- 229960000396 atropine Drugs 0.000 claims 13
- 229940092705 beclomethasone Drugs 0.000 claims 13
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 13
- 229960002179 ephedrine Drugs 0.000 claims 13
- 229960005139 epinephrine Drugs 0.000 claims 13
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 13
- 229960002428 fentanyl Drugs 0.000 claims 13
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 13
- 229960000676 flunisolide Drugs 0.000 claims 13
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 13
- 229960001361 ipratropium bromide Drugs 0.000 claims 13
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims 13
- 229940039009 isoproterenol Drugs 0.000 claims 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 13
- 229960005414 pirbuterol Drugs 0.000 claims 13
- 229960005205 prednisolone Drugs 0.000 claims 13
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 13
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims 12
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical group FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims 12
- 150000004677 hydrates Chemical class 0.000 claims 11
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 10
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 10
- 229960000289 fluticasone propionate Drugs 0.000 claims 9
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 8
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 8
- 229960001334 corticosteroids Drugs 0.000 claims 8
- 229960000265 cromoglicic acid Drugs 0.000 claims 8
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 8
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 8
- 230000003287 optical effect Effects 0.000 claims 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 7
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 7
- 229960004217 benzyl alcohol Drugs 0.000 claims 7
- 229960004017 salmeterol Drugs 0.000 claims 7
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- JHIIPMNJGTTZQF-UHFFFAOYSA-N cyclopentyl n-[1-(diphenylcarbamoyl)-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indol-5-yl]carbamate Chemical compound C=1N(C(=O)N(C=2C=CC=CC=2)C=2C=CC=CC=2)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C JHIIPMNJGTTZQF-UHFFFAOYSA-N 0.000 claims 6
- GLLWUVJQYRZNHR-UHFFFAOYSA-N cyclopentyl n-[1-(hydroxycarbamoyl)-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indol-5-yl]carbamate Chemical compound C=1N(C(=O)NO)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C GLLWUVJQYRZNHR-UHFFFAOYSA-N 0.000 claims 6
- JCSUFOPUYUYANB-UHFFFAOYSA-N cyclopentyl n-[1-carbamoyl-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indol-5-yl]carbamate Chemical compound C=1N(C(N)=O)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C JCSUFOPUYUYANB-UHFFFAOYSA-N 0.000 claims 6
- IXVQHPKKDLCTHC-UHFFFAOYSA-N cyclopentyl n-[1-formyl-3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]indol-5-yl]carbamate Chemical group C=1N(C=O)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C IXVQHPKKDLCTHC-UHFFFAOYSA-N 0.000 claims 6
- FPACABIHUTXCLO-UHFFFAOYSA-N cyclopentyl n-[3-[[2-methoxy-6-[(2-methylphenyl)sulfonylcarbamoyl]phenyl]methyl]-1-[methyl(phenyl)carbamoyl]indol-5-yl]carbamate Chemical compound C=1N(C(=O)N(C)C=2C=CC=CC=2)C2=CC=C(NC(=O)OC3CCCC3)C=C2C=1CC=1C(OC)=CC=CC=1C(=O)NS(=O)(=O)C1=CC=CC=C1C FPACABIHUTXCLO-UHFFFAOYSA-N 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 claims 6
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 5
- 229960002576 amiloride Drugs 0.000 claims 5
- 239000000890 drug combination Substances 0.000 claims 5
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- QUQBHBRVKLEOEI-UBWIUKTRSA-N aldosterone hemiacetal Chemical compound C([C@@]12C)CC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](OC2O)C[C@]32[C@@H](C(=O)CO)CC[C@H]31 QUQBHBRVKLEOEI-UBWIUKTRSA-N 0.000 claims 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 4
- 229960002537 betamethasone Drugs 0.000 claims 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 4
- 229960004544 cortisone Drugs 0.000 claims 4
- 229960003957 dexamethasone Drugs 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 4
- 229960002011 fludrocortisone Drugs 0.000 claims 4
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 claims 4
- 229960000890 hydrocortisone Drugs 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229960001664 mometasone Drugs 0.000 claims 4
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 4
- 229960004618 prednisone Drugs 0.000 claims 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 4
- 230000000087 stabilizing effect Effects 0.000 claims 4
- 230000003637 steroidlike Effects 0.000 claims 4
- 239000002244 precipitate Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- 238000001647 drug administration Methods 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 238000005054 agglomeration Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940038482 beclomethasone dipropionate monohydrate Drugs 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/234,825 US7074388B2 (en) | 1998-12-10 | 2002-09-03 | Water stabilized medicinal aerosol formulation |
| PCT/US2003/027245 WO2004022035A1 (en) | 2002-09-03 | 2003-09-03 | Water stabilized medicinal aerosol formulation related applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502160A JP2006502160A (ja) | 2006-01-19 |
| JP2006502160A5 true JP2006502160A5 (enExample) | 2006-03-02 |
Family
ID=31977472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004534386A Pending JP2006502160A (ja) | 2002-09-03 | 2003-09-03 | 水安定化エアゾル薬剤組成 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7074388B2 (enExample) |
| EP (1) | EP1569617A4 (enExample) |
| JP (1) | JP2006502160A (enExample) |
| AU (1) | AU2003272251A1 (enExample) |
| CA (1) | CA2497171C (enExample) |
| DE (1) | DE03754425T1 (enExample) |
| ES (1) | ES2247959T1 (enExample) |
| MX (1) | MXPA05002337A (enExample) |
| WO (1) | WO2004022035A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60133203T3 (de) * | 2000-07-31 | 2012-02-23 | Nycomed Danmark Aps | Fentanyl Zusammensetzung für nasale Anwendung |
| EP1415647A1 (en) * | 2002-10-23 | 2004-05-06 | CHIESI FARMACEUTICI S.p.A. | "Long-acting beta-2 agonists ultrafine formulations" |
| ME00420B (me) * | 2003-03-20 | 2011-12-20 | Boehringer Ingelheim Pharmaceuticals Inc | Formulacija, za inhalator u kojem se odmjerava doza, u kojoj se kao propelenti koriste hidro-fluoro-alkani |
| RU2364400C2 (ru) * | 2003-04-14 | 2009-08-20 | Вектура Лтд | Фармацевтические композиции |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| AR041873A1 (es) * | 2003-10-30 | 2005-06-01 | Pablo Cassara Srl Lab | Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante |
| GB0501956D0 (en) * | 2005-01-31 | 2005-03-09 | Arrow Internat | Nebulizer formulation |
| GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
| EP2211956A4 (en) | 2007-10-10 | 2014-07-09 | Parion Sciences Inc | DISPOSAL OF OSMOLYTES WITH A NOSE CANNULA |
| EP2477601B1 (en) * | 2009-09-15 | 2017-09-13 | Union Carbide Chemicals & Plastics Technology LLC | Personal care compositions with ethylene acrylic acid copolymer aqueous dispersions |
| GB0918149D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
| US8986663B2 (en) | 2010-11-04 | 2015-03-24 | Rohm And Haas Company | Skin care compositions |
| US8778383B2 (en) | 2011-06-07 | 2014-07-15 | Parion Sciences, Inc. | Methods of treatment |
| US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| CA2938994A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Inhalable formulations of sodium cromolyn with improved bioavailability |
| CN106535889A (zh) | 2014-02-10 | 2017-03-22 | 帕塔拉制药有限责任公司 | 用于治疗肺疾病的肥大细胞稳定剂 |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS |
| AU2017339366A1 (en) | 2016-10-07 | 2019-04-11 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of pulmonary fibrosis |
| SG11202012005VA (en) | 2018-06-08 | 2021-01-28 | Toko Yakuhin Kogyo Co Ltd | Fluticasone furoate nasal preparation composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202519D0 (en) * | 1992-02-06 | 1992-03-25 | Glaxo Group Ltd | Medicaments |
| DE4446891A1 (de) * | 1994-12-27 | 1996-07-04 | Falk Pharma Gmbh | Stabile wäßrige Budesonid-Lösung |
| US6458338B1 (en) * | 1998-09-22 | 2002-10-01 | Aeropharm Technology Incorporated | Amino acid stabilized medicinal aerosol formulations |
| DE19847969A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Lagerfähig flüssige Formulierung mit Formoterol |
| US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
| US6540983B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
| US6447750B1 (en) * | 2000-05-01 | 2002-09-10 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US6565833B1 (en) * | 2000-05-01 | 2003-05-20 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US6548049B1 (en) * | 2000-05-01 | 2003-04-15 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
-
2002
- 2002-09-03 US US10/234,825 patent/US7074388B2/en not_active Expired - Fee Related
-
2003
- 2003-09-03 DE DE03754425T patent/DE03754425T1/de active Pending
- 2003-09-03 AU AU2003272251A patent/AU2003272251A1/en not_active Abandoned
- 2003-09-03 CA CA002497171A patent/CA2497171C/en not_active Expired - Fee Related
- 2003-09-03 WO PCT/US2003/027245 patent/WO2004022035A1/en not_active Ceased
- 2003-09-03 ES ES03754425T patent/ES2247959T1/es active Pending
- 2003-09-03 EP EP03754425A patent/EP1569617A4/en not_active Withdrawn
- 2003-09-03 JP JP2004534386A patent/JP2006502160A/ja active Pending
- 2003-09-03 MX MXPA05002337A patent/MXPA05002337A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100337614C (zh) | 医用气溶胶制剂 | |
| US6261539B1 (en) | Medicinal aerosol formulation | |
| AU759746B2 (en) | Pharmaceutical aerosol compositions | |
| AU2001245190B2 (en) | A medicinal aerosol formulation | |
| JP2006502160A (ja) | 水安定化エアゾル薬剤組成 | |
| SK92494A3 (en) | Pharmaceutical agent | |
| EP1545634B1 (en) | Method of preparing dry powder inhalation compositions | |
| RS57687B1 (sr) | Pod pritiskom stabilan aerosolni rastvor kompozicije glikopironijum bromida i kombinacije formoterola | |
| JP2018008942A (ja) | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 | |
| JP2016041713A5 (enExample) | ||
| AU2001245190A1 (en) | A medicinal aerosol formulation | |
| RS57269B1 (sr) | Stabilna pod pritiskom kompozicija aerosolnog rastvora glikopironijum bromida i kombinacije formoterola | |
| RS65537B1 (sr) | Sastavi, postupci i sistemi za isporuku aerosolnog leka | |
| CA2912927A1 (en) | Compositions, methods & systems for respiratory delivery of three or more active agents | |
| CN102573791B (zh) | 改进的制剂 | |
| CN104955448A (zh) | 适用于吸入治疗的包含多组分结晶颗粒的药物组合物 | |
| RU2582218C2 (ru) | Способ получения дозирующего распыляющего ингалятора для лечения респираторного заболевания | |
| RS54721B1 (sr) | Farmaceutske aerosolne formulacije formoterola i beklometazon dipropionata | |
| EA007377B1 (ru) | Композиции для ингаляции | |
| WO2002007672A2 (en) | A medicinal aerosol formulation | |
| AU2005293328A1 (en) | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister | |
| JP4744876B2 (ja) | 乾燥粉末吸入組成物の製造方法 | |
| US20040241103A1 (en) | Pharmaceutical aerosol compositions | |
| WO2002015883A1 (en) | A method of stabilizing a dry powder pharmaceutical formulation | |
| AU2007231727A1 (en) | Water stabilized medicinal aerosol formulation |